Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes
- PMID: 21807982
- PMCID: PMC3187001
- DOI: 10.1128/AAC.00157-11
Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes
Abstract
The integrase inhibitor (INI) dolutegravir (DTG; S/GSK1349572) has significant activity against HIV-1 isolates with raltegravir (RAL)- and elvitegravir (ELV)-associated resistance mutations. As an initial step in characterizing the different resistance profiles of DTG, RAL, and ELV, we determined the dissociation rates of these INIs with integrase (IN)-DNA complexes containing a broad panel of IN proteins, including IN substitutions corresponding to signature RAL and ELV resistance mutations. DTG dissociates slowly from a wild-type IN-DNA complex at 37°C with an off-rate of 2.7 × 10(-6) s(-1) and a dissociative half-life (t(1/2)) of 71 h, significantly longer than the half-lives for RAL (8.8 h) and ELV (2.7 h). Prolonged binding (t(1/2), at least 5 h) was observed for DTG with IN-DNA complexes containing E92, Y143, Q148, and N155 substitutions. The addition of a second substitution to either Q148 or N155 typically resulted in an increase in the off-rate compared to that with the single substitution. For all of the IN substitutions tested, the off-rate of DTG from IN-DNA complexes was significantly slower (from 5 to 40 times slower) than the off-rate of RAL or ELV. These data are consistent with the potential for DTG to have a higher genetic barrier to resistance, provide evidence that the INI off-rate may be an important component of the mechanism of INI resistance, and suggest that the slow dissociation of DTG may contribute to its distinctive resistance profile.
Figures





Similar articles
-
Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics.PLoS One. 2013 Oct 16;8(10):e77448. doi: 10.1371/journal.pone.0077448. eCollection 2013. PLoS One. 2013. PMID: 24146996 Free PMC article.
-
Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.J Virol. 2015 Oct;89(20):10482-8. doi: 10.1128/JVI.01725-15. Epub 2015 Aug 5. J Virol. 2015. PMID: 26246578 Free PMC article.
-
Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.Intervirology. 2012;55(4):287-95. doi: 10.1159/000336658. Epub 2012 Mar 23. Intervirology. 2012. PMID: 22456540
-
[Resistance profile and genetic barrier of dolutegravir].Enferm Infecc Microbiol Clin. 2015 Mar;33 Suppl 1:20-5. doi: 10.1016/S0213-005X(15)30005-7. Enferm Infecc Microbiol Clin. 2015. PMID: 25858608 Review. Spanish.
-
Differences among HIV-1 subtypes in drug resistance against integrase inhibitors.Infect Genet Evol. 2016 Dec;46:286-291. doi: 10.1016/j.meegid.2016.06.047. Epub 2016 Jun 25. Infect Genet Evol. 2016. PMID: 27353185 Review.
Cited by
-
3'-processing and strand transfer catalysed by retroviral integrase in crystallo.EMBO J. 2012 Jun 29;31(13):3020-8. doi: 10.1038/emboj.2012.118. Epub 2012 May 11. EMBO J. 2012. PMID: 22580823 Free PMC article.
-
Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0164321. doi: 10.1128/AAC.01643-21. Epub 2021 Oct 25. Antimicrob Agents Chemother. 2022. PMID: 34694877 Free PMC article. Clinical Trial.
-
Elvitegravir: a review of its use in adults with HIV-1 infection.Drugs. 2014 Apr;74(6):687-97. doi: 10.1007/s40265-014-0206-8. Drugs. 2014. PMID: 24671908 Review.
-
ABCG2 Deficiency Does Not Alter Dolutegravir Metabolism and Pharmacokinetics.J Pharmacol Exp Ther. 2020 Jul;374(1):38-43. doi: 10.1124/jpet.119.264424. Epub 2020 Apr 17. J Pharmacol Exp Ther. 2020. PMID: 32303561 Free PMC article.
-
Selectivity for strand-transfer over 3'-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site.Nucleic Acids Res. 2016 Aug 19;44(14):6896-906. doi: 10.1093/nar/gkw592. Epub 2016 Jul 1. Nucleic Acids Res. 2016. PMID: 27369381 Free PMC article.
References
-
- Asante-Appiah E., Skalka A. M. 1999. HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv. Virus Res. 52:351–369 - PubMed
-
- Boros E. E., Johns B. A., Garvey E. P., Koble C. S., Miller W. H. 2006. Synthesis and HIV-integrase strand transfer inhibition activity of 7-hyroxyl[1,3]thiazolo[5,4-b]pyridin-5(4H)-ones. Bioorg. Med. Chem. Lett. 16:5668–5672 - PubMed
-
- Ceccherini-Silberstein F., et al. 2009. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev. 11:17–29 - PubMed
-
- Chiu T. K., Davies D. R. 2004. Structure and function of HIV-1 integrase. Curr. Top. Med. Chem. 4:965–977 - PubMed
-
- Cooper D. A., et al. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 359:355–365 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials